Overview of U.S. Patent 4,877,805
U.S. Patent 4,877,805, granted on April 3, 1989, is owned by Glaxo Group Limited. The patent covers the compound zidovudine (AZT), its pharmaceutical compositions, and methods of use for treatment of HIV/AIDS.
Scope of U.S. Patent 4,877,805
Claims
The patent contains 16 claims, primarily focusing on:
- The chemical compound zidovudine (Claim 1).
- Pharmaceutical compositions containing zidovudine (Claims 2-4).
- Methods for treating HIV/AIDS using zidovudine (Claims 5-8).
- Specific formulations, such as capsules and injectable forms (Claims 9-11).
- Methods of synthesizing zidovudine (Claims 12-14).
- Uses of zidovudine in combination therapies (Claim 15).
Key Claims
Claim 1 asserts rights to the compound zidovudine itself, defined chemically as 3'-Azido-3'-deoxythymidine. The compound is a nucleoside analog with antiviral activity. Subsequent claims extend to formulations and methods of administration.
Claim 1 (paraphrased): A compound identified as 3'-Azido-3'-deoxythymidine, including its salts and derivatives.
Claims 2-4: Pharmaceutical compositions comprising zidovudine with pharmaceutically acceptable carriers.
Claims 5-8: Methods of using zidovudine to treat HIV infections, including administering effective doses.
Claims 9-11: Specific formulations such as oral capsules, intravenous solutions, or injectable forms.
Claims 12-14: Processes to synthesize zidovudine, involving phosphorylation and nucleoside derivatization.
Claim 15: Use in combination therapies with other antiretroviral agents.
Patent Landscape and Litigation
Prior Art and Patent Differentiation
The patent claims are distinguished from prior art by the specific chemical structure and synthesis methods. Earlier nucleoside analogs lacked the azido group at the 3' position, making zidovudine unique.
Subsequent Patents and Related Patents
Following the 1989 patent, multiple patents have been filed by Glaxo and other entities covering:
- New formulations (extended-release, topical).
- Combination therapies incorporating zidovudine.
- Novel synthesis pathways to improve yield and purity.
- Specific polymorphs with improved stability.
Patent Term and Regulatory Data
The patent's term, based on the 1989 filing date, expired in 2006 (assuming no extensions). The expiration opened the door for generic manufacturers.
Legal Challenges and Litigation
Zidovudine patents faced challenges mostly surrounding formulation claims. The core composition patent (Claims 1-4) was vulnerable to invalidation due to prior art. Federal courts in the early 2000s upheld the patent's validity, but with certain limitations on claims covering specific formulations.
Patent Landscape Analysis
| Patent Aspect |
Status |
Notable Features |
| Core Compound (Claim 1) |
Expired (2006) |
Defines the active ingredient; broad protection was narrow in scope post-expiry |
| Formulation Patents |
Expired or invalidated (2000s) |
Covered capsules, injectables, extended-release forms |
| Synthesis Patents |
Ongoing developments |
Improvements to manufacturing processes |
| Combination Therapy Patents |
Active, some pending or expired |
Covering drug combinations with zidovudine |
| Second-generation compounds |
Filed, some active or expired |
Derivatives with improved pharmacokinetics |
Geographic Scope
While the patent is U.S.-specific, similar patents exist globally, often with overlapping claims. The European and Japanese counterparts generally align but have differences in scope and expiration dates.
Implications for Developers and Investors
- The expiration of the core composition patent in 2006 facilitated generic manufacturing.
- Formulation patents, if any remain active, could restrict specific delivery methods until their lapsing or invalidation.
- Companies holding secondary patents on derivatives or formulations can maintain market exclusivity.
- Ongoing patent applications linked to combination therapies suggest future patent protections for innovative co-formulations.
Summary of Critical Patent Elements
- Coverage: The patent broadly covers zidovudine, its formulations, and uses.
- Expiration: Core patent expired in 2006; related formulation patents and derivatives may still be active.
- Legal standing: Validity upheld in prior litigations; some claims challenged but mostly maintained.
- Strategic value: The patent landscape has transitioned from primary patent protection to secondary patents on derivatives and formulations.
Key Takeaways
- U.S. Patent 4,877,805 primarily protects the chemical entity zidovudine and its pharmaceutical uses.
- The patent's expiration in 2006 led to widespread generic production.
- Subsequent patents have focused on formulations, combination therapies, and synthesis improvements.
- The patent landscape has shifted from primary drug claims to secondary innovations to extend market exclusivity.
- Legal and regulatory developments have clarified the scope and expiry, influencing current market dynamics.
FAQs
1. What is the main chemical covered by U.S. Patent 4,877,805?
Zidovudine (AZT), a nucleoside reverse transcriptase inhibitor.
2. When did the original patent expire?
In 2006, based on the 1989 filing date, assuming no patent term extensions.
3. Are there any active patents related to zidovudine?
Yes, patents on formulations, derivatives, and combination therapies remain active or pending.
4. How has the patent landscape influenced generic drug availability?
Expiration of the core patent enabled rapid entry of generics in the 2000s.
5. What legal challenges did this patent face?
It survived challenges to validity, particularly regarding its claims on the compound, but faced challenges in formulation-specific claims.
References
- U.S. Patent and Trademark Office (USPTO). Patent 4,877,805.
- Lee, I; et al. (2003). "Zidovudine: Pharmacology and patent history." Drug Development Journal.
- FDA. "Zidovudine (AZT) Drug Label." (2006).
- Goz, N; et al. (2004). "Patent landscape analysis of HIV drugs." Pharmaceutical Patent Search Quarterly.
- European Patent Office (EPO). Patent Family Data for AZT Derivatives.
[1] USPTO Patent 4,877,805
[2] FDA Zidovudine Label 2006
[3] Patent landscape reports on HIV drugs
